Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04331366 · ClinicalTrials.gov registry record · NA
Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19
A NA study, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT04331366: Completed NA study, sponsored by Emory University.
NCT04331366 is a NA study that has completed, run by Emory University. The registered enrollment target is 2 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04331366, a NA study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
The objective of this study is to determine the safety, feasibility and efficacy of a bidirectional oxygenation Positive End Expiratory Pressure (PEEP) mouthpiece in coronavirus disease 2019 (COVID-19) patients requiring supplemental oxygen by non-rebreather mask.
Primary Outcome
Pulse oximetry is a way to assess whether or not a patient needs help breathing. Oxygen saturation levels for healthy individuals are 95% and above.
Interventions
- DEVICE GO2 PEEP MOUTHPIECE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-04-08 |
| Est. Completion | 2020-08-31 |
| Phase | NA |
What the finished NCT04331366 record still lists
NCT04331366 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which GO2 PEEP MOUTHPIECE is the first listed.
NCT04331366 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04331366 about?
NCT04331366 is a clinical study titled "Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19". The objective of this study is to determine the safety, feasibility and efficacy of a bidirectional oxygenation Positive End Expiratory Pressure (PEEP) mouthpiece in coronavirus disease 2019 (COVID-19) patients requiring supplemental oxygen by non-rebreather mask.
What is the current status of trial NCT04331366?
This trial is currently completed. It is a NA study. The enrollment target is 2 participants. The study started on 2020-04-08. Estimated completion is 2020-08-31.
What interventions are being tested in trial NCT04331366?
The interventions under investigation include: GO2 PEEP MOUTHPIECE (DEVICE).
Who is sponsoring clinical trial NCT04331366?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04331366's enrollment target sits among peer trials
2 1997th of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI